» » Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer
Download Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer epub book
ISBN:0812991842
Author: Robert Bazell
ISBN13: 978-0812991840
Title: Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer
Format: docx txt lit lrf
ePUB size: 1840 kb
FB2 size: 1640 kb
DJVU size: 1359 kb
Language: English
Category: Medicine and Health Sciences
Publisher: Random House; 1 edition (August 25, 1998)
Pages: 240

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer by Robert Bazell



Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. This is a very detailed look at the development of a new kind of treatment for breast cancer. I have a family member affected, and I am a physician, so it is good to know as much as possible, though I do not treat breast cancer as a primary care physician. The lives saved and sadly those lost.

Bazell paints a complete picture of the development of the nontoxic "miracle" drug known as Herceptin, which purportedly halts and reverses the "overexpressed Her-2 protein" affecting 30% of breast cancer patients, shrinking and even eliminating spreading tumors  . 4 more to go!!! I had 4 rounds of AC then 12 rounds of Taxol and Herceptin with 3 rounds of a cousin to Herceptin which I think was prujeta?.

Her-2: The Making of Herc. has been added to your Cart. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Terrific book about discovery of Her-2 and Herceptin. Although published in 1998, it gives the back story of these discoveries and the journey to FDA approval. Very informative and inspirational. One person found this helpful.

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Five years later she remains cancer-free.

Что Говорит Цвет Менструальной Крови о Вашем Здоровье - Продолжительность: 8:16 AdMe.

Her-2 is the biography of Herceptin, the drug that offers promise for hundreds of thousands of breast cancer patients. In his book, Robert Bazell presents how Herceptin was born in the middle of dramatic discoveries, scientific investigations, money from Hollywood, politics, strong egos, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient’s bedside. time they had left on an unproven treatment

Her-2 is the biography of Herceptin, the drug. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu-a protein that makes cancer cells grow especially quickly- produced by a gene found in 25 to 30 percent of all breast tumors

Additional Two years later she underwent a mastectomy & chemotherapy, breast cancer aggressive Barbara Bradfield had returned & spread his lungs. The outlook is bleak. Five years later she remains free of cancer. Her-2 is the biography of Herceptin, a drug that dramatic reactions Barbara Bradfield & other women has caused, the tests & features the promise of hundreds of thousands of patients with breast cancer. In contrast into chemotherapy or radiation, Herceptin is never clear side effects.

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer reads like a novel at first. Oncologist Dennis Slamon has spent 13 years "obsessed with a molecule called Her-2," which he believed "held the key to nothing less than curing breast cancer. He keeps bringing the reader back to the threads of the personal stories we are the women with breast cancer and their determination to recapture their health. This is what makes Her-2 so compelling.

In the introduction to this narrative about the making of the new breast cancer drug Herceptin, geneticist Mary-Claire King observes that "good science makes a great yarn. That sums up the appeal of Robert Bazell's new book. Bazell, chief science correspondent for NBC News, proves himself a diligent reporter and entertaining writer in detailing the story of Herceptin. He gives us an inside look at the egos, politics, economics and emotions that play a major role in science and biotechnology.

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.        Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.        Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.From the Hardcover edition.
Reviews: 7
Kupidon
Reading this book, and yes I saw the movie...again pointed out, How Very BLESSED I am to be alive! If Dr Slamon had given up on his fight to bring Herceptin to fruition...I and a very large number of women would have been dead years ago! I was able to really experience all the problems and difficulties he and many others faced. Reading about those who fought hard for its inception increases my respect and admiration. If not for those who worked so diligently to bring these developments to life many would be dead. In 1999 I was diagnosed with this aggressive form of Cancer. I truly appreciate all those women who went before me. After 8 years on Herceptin, with an OK from Dr Slamon, My weekly Herceptin was discontinued. I have been Blessed now with 16 years of life, when I had originally been given a few months.
Pedar
A compelling read about the discovery of the drug Herceptin. My education crossed paths with both Dr. Dennis Salmon and Dr. John Glaspy during my internship at UCLA in 1992. Both of them were my attending physicians during my internship. In fact, my first rotation out of medical school (from UCSF) was on the solid oncology unit at UCLA and a few short months later it was on the bone marrow transplant unit. I encountered many deathly sick patients and sadly many died. I wish I knew what Dr. Slamon and Dr. Glaspy were doing at the very time of my internship to help save the lives of their patients. They are to be commended for advancing the treatments for breast cancer. All these years later I wish that my internship had started with one of the oncology attendings telling me this: "Your internship is going to suck. You will take care of devastatingly sick patients many of whom will die. You will be fatigued and get little sleep. You will become attached to them and feel the pain that they and their families go through. And often, it will be hopeless, but we want you to know that as you are on the wards taking care of them we are working on the advances that one day will help to save their lives. If I had only known about those first patients ever to receive HERCEPTIN it might have changed not only my year of internship but all the years since. I recognize that it is in the 26 years since doing my internship that many new treatments have in fact come along to save or at least add years to people's lives. It was 9 years after my internship that the drug GLEEVEC was approved--I wish it had been available to save the life of one of my patients, JK. I watched as the attendings and fellows and residents and myself were completely helpless in saving him. Robert Bazell is to be commended for not only reporting the science, but the politics and bureaucracy of bringing a life saving drug to market.
Sennnel
Very interesting to read since I am now using this miracle drug for a recent diagnosis. I was surprised to see it was published so long ago (1998) and I'd love it to be updated. The personal stories of the women who fought for this drug, and those who didn't get to benefit from it, are the most compelling. I am so grateful to benefit from all the pioneering work that's been done. So why does this still cost $10,000.00 for each infusion 16 years later? I'm getting it for a year, maybe $180,000.00, nearly all covered by insurance. An update on the costs of developing, marketing, and distributing the drug would be helpful.
Уou ll never walk alone
Terrific book about discovery of Her-2 and Herceptin. Although published in 1998, it gives the back story of these discoveries and the journey to FDA approval. Very informative and inspirational. As a breast cancer patient, I am grateful for everyone who participated in the development of the drug and the women who participated in the trials that resulted in widespread availability for women who are Her-2 positive.
Dog_Uoll
I am a breast cancer patient currently winding down on my treatment of Herceptin....4 more to go!!! I had 4 rounds of AC then 12 rounds of Taxol and Herceptin with 3 rounds of a cousin to Herceptin which I think was prujeta??. Then a bilateral with no des ease evident and no lymph nodes affected. Then 9 months of Herceptin only....this is the treatment for HER2 nue positive in 2013/2014.
Adrielmeena
It's a very clear, and sometimes passionate, history about how to develop an biopharmaceutical, specially a very difficult one, as a monoclonal antibody.
Also and not least, several pesonals histories on women suffering breast cancer
Conjulhala
It had really motivating stories of emotional experiences, I read it mostly for the science, and this book contains a lot of new terms that really help enhance information for a future oncologist.
DR. DENNIS SLAMMON IS STILL AT RONALD REAGAN/UCLA MED CENTER IN LOS ANGELES CALIF. HE IS STILL DEPT. HEAD OF ONCOLOGY HEMATOLOGY IN 2014. YOU MUST READ THIS BOOK IF YOU GET A DIAGNOSIS OF BREASTCANCER. IT COULD SAVE YOU OR SOMEONE ELSE WITH THIS DREADFUL DIAGNOSIS.